Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | - | 0 | 0 | - |
| Operating profit | $m | -158 | -206 | ||||||
| Net profit | $m | - | - | - | - | - | -149 | -190 | -442 |
| EPS reported | $ | -1.26 | -1.76 | ||||||
| Operating cashflow per share | $ | -1.02 | -1.43 | ||||||
| Capex per share | $ | 0.02 | 0.00 | ||||||
| FCF per share | $ | -1.04 | -1.43 | ||||||
| Free cash flow | $m | -122 | -146 | ||||||
| Net debt | $m | -546 | -917 | ||||||
| Book value equity | $m | -356 | 1,118 | ||||||
| Book value per share | $ | -3.02 | 10.94 | ||||||
| Number of shares | m | 117.95 | 102.23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -8.60 | 1.49 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -25.08 | -11.46 | ||||||
| EV/EBITDA LTM | x | -18.46 | -3.85 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -4.86% | -14.43% | ||||||
| FCF Yield | % | -3.99% | -8.73% | ||||||
| Quality | |||||||||
| ROE | % | 41.79% | -55.41% | ||||||
| ROIC | % | -24.48% | -18.25% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.37 | -14.28 | ||||||
| Net Debt/EBITDA | x | 0.95 | 0.61 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | -17.81% | -54.86% | ||||||
| Net debt/Equity | x | 1.53 | -0.82 | ||||||
| Gross debt/equity | x | -0.03 | 0.01 | ||||||
ETFs that hold Kailera Therapeutics
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Roundhill Investments - GLP-1 & Weight Loss ETF | OZEM | 5 | 5.35% |
Funds with Kailera Therapeutics among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kailera Therapeutics, Inc. (KLRA)
Not enough data to calculate KvantraRank
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Roundhill Investments - GLP-1 & Weight Loss ETF | OZEM | 5 | 5.35% |
Funds with Kailera Therapeutics among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free